Medication info

Ilyang Gentaduo Tablets 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Bright pink, biconvex, oval-shaped film-coated tablets
Packaging
30 tablets/box [6 tablets/PTP x 5]
Approval status
Expired

MFDS item code 202003643 · Approved 2020.05.19

This product's status changed to Expired on 2025.05.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood glucose levels in patients with type 2 diabetes who use a combination of linagliptin and metformin. It is effective for those who find it difficult to manage blood glucose while following dietary and exercise treatments. Combination therapy can lead to more stable blood glucose control. By improving patients' blood glucose levels, this drug contributes to the prevention of complications. Therefore, this drug is used as an adjunct to dietary and exercise therapy.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients inadequately controlled with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients inadequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication can cause a serious side effect known as lactic acidosis, and should not be administered to patients with certain medical conditions. In particular, patients with severely impaired kidney function or liver dysfunction may be at risk if this medication is used. Additionally, it is necessary to discontinue this medication during acute infections, dehydration, heart failure, or other situations where the patient's physical condition rapidly deteriorates. There is a risk of hypoglycemia, so when used with insulin or sulfonylureas, blood glucose should be monitored closely. This medication may lower vitamin B12 levels, so it is advisable to regularly check for vitamin B12 deficiency during prolonged use. It is safer for pregnant or nursing women not to use this medication, and they should consult a doctor if necessary. Since elderly patients often have decreased kidney function, frequent kidney function tests are required to determine the appropriate dosage. This medication may interact with various other drugs, so it is essential to inform the healthcare provider of any other medications being taken. In case of overdose, there is a risk of lactic acidosis, so the dosage should be strictly adhered to, and if abnormal symptoms appear, a medical institution should be visited immediately. When storing, keep out of reach of children and store in a moisture-free environment.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 111 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesiculobullous dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • elevated lipase
  • elevated amylase
  • stomatitis
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbance
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute choledochitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • hemorrhoidal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • discomfort in the chest
  • weakness
  • nosebleed
  • oropharyngeal pain
  • dysphonia
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusional state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store it at room temperature between 1°C and 30°C to maintain its efficacy.

Appearance and packaging

Appearance

Bright pink, biconvex, oval-shaped film-coated tablets

Package unit

30 tablets/box [6 tablets/PTP x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.